Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting medicines, known simply as TCEs, are being adopted from the oncology ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The ...

California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...

Ouro Medicines’ drugs deplete disease-driving ... Monograph Capital founded the startup in partnership with GSK. 3D medical animation services have emerged as a groundbreaking tool in the ...

Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company ... The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by ...